This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/mixture/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06795/identifier/wikipedia/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06795/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06795/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://www.drugs.com/international/
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06795
rdf:type
n3:Drug
n3:description
Mafenide is a sulfonamide-type medication used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.
n3:dosage
n13:271B547D-363D-11E5-9242-09173F13E4C5 n13:271B547E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Maghsoudi H, Salehi F, Khosrowshahi MK, Baghaei M, Nasirzadeh M, Shams R: Comparison between topical honey and mafenide acetate in treatment of burn wounds. Ann Burns Fire Disasters. 2011 Sep 30;24(3):132-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22396671
n3:group
approved
n3:indication
Mafenide is indicated in the treatment of severe burns.
owl:sameAs
n10:DB06795
dcterms:title
Mafenide
adms:identifier
n6:D02351 n7:Mafenide n17:DB06795
n3:mechanismOfAction
The precise mechanism of mafenide is unknown. However, mafenide reduces the bacterial population in the avascular burn tissue and promotes spontaneous heeling of deep burns.
n3:routeOfElimination
Renal—Metabolite rapidly excreted in urine in high concentrations; however, the parent compound has not been detected in urine.
n3:synonym
Bensulfamide 4-Homosufanilamide 4-(aminomethyl)benzenesulfonamide Maphenidum
n3:toxicity
Since mafenide is metabolized to a carbonic anhydrase inhibitor, metabolic acidosis could occur. Mafenide is contraindicated in persons with renal impairment or sulfonamide hypersensitivity.
n3:mixture
n14:271B547C-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
U.S. Patent 2,288,531.
foaf:page
n16:Mafenide.html
n3:IUPAC-Name
n4:271B5483-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5489-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5488-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5485-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5486-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5487-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5481-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5482-363D-11E5-9242-09173F13E4C5 n4:271B547F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5480-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:D06BA03
n3:H-Bond-Acceptor-Count
n4:271B548F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5490-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B548A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B548B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B548D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B548C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B548E-363D-11E5-9242-09173F13E4C5
n3:absorption
Mafenide is absorbed through devascularized areas into the systemic circulation following topical administration.
n3:affectedOrganism
Pseudomonas aeruginosa Gram negative and gram positive bacteria Bacteria
n3:casRegistryNumber
138-39-6
n3:Bioavailability
n4:271B5495-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5497-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5498-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5499-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5494-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5493-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5496-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5484-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5491-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5492-363D-11E5-9242-09173F13E4C5